SkinBioTherapeutics PLC (AIM:SBTX), a life science company focused on skin health, today launched a probiotic food supplement to help alleviate the symptoms associated with psoriasis. The launch is timed to coincide with World Psoriasis Day.
The product, AxisBiotix-Ps, is now being shipped to the UK and US with a subscription price per sachet of £1.50/US$2.00.
In May 2021, SkinBioTherapeutics reported on the outcomes of the study for participants that self-identified as suffering from psoriasis. The results were "very positive" and provided definitive support for the commercial development of AxisBiotix-Ps as a probiotic food supplement to help alleviate the symptoms of psoriasis, SkinBioTherapeutics said.
Of participants that completed the study, 76% reported a reduction in itchiness and 73% reported their skin felt less irritable.
“The launch of our first commercial product is a momentous occasion for SkinBioTherapeutics," said Stuart Ashman, the chief executive officer of SkinBioTherapeutics. "The interest in AxisBiotix-Ps, and overwhelmingly positive response from participants, has been hugely encouraging. We're delighted to introduce our product to the market on the most important of days for the global psoriasis community, as planned.
"Since the exciting results from the consumer study, announced back in May this year, we have seen a growing interest in our product. We have been working hard ever since to establish a reliable supply chain to ensure a continuous supply to all our customers upon launch.”